fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Best Pharma Mutual Funds

Top 4 Best Performing Pharma Mutual Funds 2022

Updated on January 23, 2022 , 182809 views

Planning to invest in pharma funds? Pharma Mutual Funds are sector-specific fund that invests in different pharmaceutical companies. Due to the huge population of India, there has always been a high demand for medicines and other health care needs because of which pharma companies have been earning good profits. Globally, India is the third-largest pharmaceutical production by volume and 14th by value. According to the Indian Economic Survey 2021, the domestic Market is expected to grow three times in the next decade. India’s domestic pharmaceutical market is likely to reach US$ 65 billion by 2024 and further expand to reach ~US$ 120-130 billion by 2030.

Best Pharma Mutual Fund

India has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and about 10,500 Manufacturing units. Export of drugs and pharmaceuticals was valued at $2001.78 bn in August 2021 with a positive growth of 1.21% over exports of $1977.76 bn in Aug'20.

Largest pharmaceutical companies in India by market capitalization (as of August 2021) are — Sun Pharmaceutical, Cipla, Lupin, Dr. Reddy’s Labs, Aurobindo Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, etc.

If you are keen to invest in the pharma sector fund, the following are the schemes listed for you.

Pharma Equity Funds in India

Pharma funds belong to the equity sectoral fund category which mainly invests in pharma and pharma related stocks. They focus to create a long-term wealth for the investors by taking advantage of growth in the Pharmaceutical sector. In India, some of the top performing funds are - Nippon India Pharma Fund, TATA India Pharma & Healthcare Fund, UTI Healthcare Fund and SBI Healthcare Opportunities Fund.

Nippon India Pharma Fund is in the market since 2004 and has delivered 21.12% returns since inception, whereas UTI Healthcare Fund was launched in 2005 and delivered returns of 18.42% since inception.

SBI Healthcare Opportunities Fund is one of the oldest pharma fund, launched in the year 1999 and has delivered 15.59% returns since its launch.

The category average of pharma funds stood at 131.79% over 1 year period ended 5 March 2010. Three out of four funds have outpaced BSE Healthcare over the same time period. The Reliance India Pharma Fund has topped the category over one year period. The category average has been 19.77% and 18.81% during three years and five years time period.

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Best Pharma Sector Funds 2022

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2021 (%)
Nippon India Pharma Fund Growth ₹286.841
↑ 1.96
₹5,397-4.3-8.512.323.716.823.9
TATA India Pharma & Healthcare Fund Growth ₹16.7893
↑ 0.09
₹583-2.2-5.81124.114.119.1
UTI Healthcare Fund Growth ₹157.273
↑ 1.38
₹846-3.7-7.511.323.112.719.1
SBI Healthcare Opportunities Fund Growth ₹220.001
↑ 1.44
₹1,943-1.1-79.722.110.820.1
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 25 Jan 22

1. Nippon India Pharma Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a CAGR/Annualized return of 21% since its launch.  Ranked 35 in Sectoral category.  Return for 2021 was 23.9% , 2020 was 66.4% and 2019 was 1.7% .

Below is the key information for Nippon India Pharma Fund

Nippon India Pharma Fund
Growth
Launch Date 5 Jun 04
NAV (25 Jan 22) ₹286.841 ↑ 1.96   (0.69 %)
Net Assets (Cr) ₹5,397 on 31 Dec 21
Category Equity - Sectoral
AMC Nippon Life Asset Management Ltd.
Rating
Risk High
Expense Ratio 0.96
Sharpe Ratio 1.37
Information Ratio 0.77
Alpha Ratio 2.53
Min Investment 5,000
Min SIP Investment 100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Dec 16₹10,000
31 Dec 17₹10,761
31 Dec 18₹11,152
31 Dec 19₹11,340
31 Dec 20₹18,875
31 Dec 21₹23,393

Nippon India Pharma Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689
Invest Now

Returns for Nippon India Pharma Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 25 Jan 22

DurationReturns
1 Month -3.5%
3 Month -4.3%
6 Month -8.5%
1 Year 12.3%
3 Year 23.7%
5 Year 16.8%
10 Year
15 Year
Since launch 21%
Historical performance (Yearly) on absolute basis
YearReturns
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%
2013 20.9%
2012 34.8%
Fund Manager information for Nippon India Pharma Fund
NameSinceTenure
Sailesh Raj Bhan1 Apr 0516.76 Yr.
Kinjal Desai25 May 183.61 Yr.

Data below for Nippon India Pharma Fund as on 31 Dec 21

Equity Sector Allocation
SectorValue
Health Care99.11%
Asset Allocation
Asset ClassValue
Cash0.89%
Equity99.11%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
12%₹643 Cr7,600,976
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 500124
10%₹515 Cr1,050,000
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
9%₹472 Cr5,000,000
↑ 500,000
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
8%₹411 Cr5,600,000
↑ 100,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
7%₹399 Cr4,200,025
↑ 1,100,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
7%₹374 Cr800,000
Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Sep 20 | TORNTPHARM
6%₹312 Cr950,328
↑ 50,000
Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 30 Jun 17 | NH
6%₹311 Cr4,858,010
↓ -92,016
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
5%₹289 Cr575,772
↓ -25,000
Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | 500488
5%₹251 Cr128,670

2. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a CAGR/Annualized return of 8.9% since its launch.  Return for 2021 was 19.1% , 2020 was 64.4% and 2019 was 5.5% .

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund
Growth
Launch Date 28 Dec 15
NAV (25 Jan 22) ₹16.7893 ↑ 0.09   (0.55 %)
Net Assets (Cr) ₹583 on 31 Dec 21
Category Equity - Sectoral
AMC Tata Asset Management Limited
Rating Not Rated
Risk High
Expense Ratio 2.28
Sharpe Ratio 1.15
Information Ratio 0.94
Alpha Ratio 8.72
Min Investment 5,000
Min SIP Investment 150
Exit Load 0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Dec 16₹10,000
31 Dec 17₹10,465
31 Dec 18₹10,191
31 Dec 19₹10,752
31 Dec 20₹17,674
31 Dec 21₹21,043

TATA India Pharma & Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹436,710.
Net Profit of ₹136,710
Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 25 Jan 22

DurationReturns
1 Month -1.5%
3 Month -2.2%
6 Month -5.8%
1 Year 11%
3 Year 24.1%
5 Year 14.1%
10 Year
15 Year
Since launch 8.9%
Historical performance (Yearly) on absolute basis
YearReturns
2021 19.1%
2020 64.4%
2019 5.5%
2018 -2.6%
2017 4.7%
2016 -14.7%
2015
2014
2013
2012
Fund Manager information for TATA India Pharma & Healthcare Fund
NameSinceTenure
Meeta Shetty9 Mar 210.82 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 31 Dec 21

Equity Sector Allocation
SectorValue
Health Care97.71%
Financial Services0.48%
Asset Allocation
Asset ClassValue
Cash1.81%
Equity98.19%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA
13%₹73 Cr867,100
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | 500124
9%₹52 Cr105,700
↑ 2,200
Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087
8%₹47 Cr500,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
7%₹43 Cr92,500
↓ -12,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP
7%₹42 Cr84,300
Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEM
6%₹37 Cr103,049
Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 16 | 524494
6%₹34 Cr158,726
Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 29 Feb 20 | NH
6%₹32 Cr505,198
↓ -50,000
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | 532843
4%₹24 Cr795,000
Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 500257
4%₹24 Cr248,000
↑ 25,000

3. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a CAGR/Annualized return of 14.4% since its launch.  Ranked 40 in Sectoral category.  Return for 2021 was 19.1% , 2020 was 67.4% and 2019 was 1.2% .

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund
Growth
Launch Date 28 Jun 99
NAV (25 Jan 22) ₹157.273 ↑ 1.38   (0.88 %)
Net Assets (Cr) ₹846 on 31 Dec 21
Category Equity - Sectoral
AMC UTI Asset Management Company Ltd
Rating
Risk High
Expense Ratio 2.74
Sharpe Ratio 1.13
Information Ratio 0.51
Alpha Ratio -0.44
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Dec 16₹10,000
31 Dec 17₹10,620
31 Dec 18₹9,821
31 Dec 19₹9,936
31 Dec 20₹16,630
31 Dec 21₹19,803

UTI Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹415,684.
Net Profit of ₹115,684
Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 25 Jan 22

DurationReturns
1 Month -2.1%
3 Month -3.7%
6 Month -7.5%
1 Year 11.3%
3 Year 23.1%
5 Year 12.7%
10 Year
15 Year
Since launch 14.4%
Historical performance (Yearly) on absolute basis
YearReturns
2021 19.1%
2020 67.4%
2019 1.2%
2018 -7.5%
2017 6.2%
2016 -9.7%
2015 12.4%
2014 43.7%
2013 23.3%
2012 24.8%
Fund Manager information for UTI Healthcare Fund
NameSinceTenure
V Srivatsa3 Mar 174.84 Yr.

Data below for UTI Healthcare Fund as on 31 Dec 21

Equity Sector Allocation
SectorValue
Health Care95.03%
Basic Materials3.2%
Asset Allocation
Asset ClassValue
Cash1.77%
Equity98.23%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | 500124
9%₹80 Cr162,934
↓ -4,127
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA
9%₹73 Cr858,390
↓ -12,324
Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087
8%₹71 Cr748,625
↓ -8,635
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Oct 13 | AUROPHARMA
7%₹60 Cr812,447
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 532843
5%₹46 Cr1,538,587
Lupin Ltd (Healthcare)
Equity, Since 31 May 18 | 500257
5%₹45 Cr468,483
↑ 53,066
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
5%₹42 Cr90,534
↓ -3,410
Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Jun 21 | 543308
4%₹33 Cr234,541
↑ 24,769
Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331
4%₹31 Cr138,401
↓ -22,021
Eris Lifesciences Ltd Registered Shs (Healthcare)
Equity, Since 31 Mar 19 | 540596
3%₹29 Cr382,137
↓ -41,995

4. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a CAGR/Annualized return of 14.4% since its launch.  Ranked 34 in Sectoral category.  Return for 2021 was 20.1% , 2020 was 65.8% and 2019 was -0.5% .

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund
Growth
Launch Date 31 Dec 04
NAV (25 Jan 22) ₹220.001 ↑ 1.44   (0.66 %)
Net Assets (Cr) ₹1,943 on 31 Dec 21
Category Equity - Sectoral
AMC SBI Funds Management Private Limited
Rating
Risk High
Expense Ratio 2.28
Sharpe Ratio 1.24
Information Ratio 0.25
Alpha Ratio 1.45
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

DateValue
31 Dec 16₹10,000
31 Dec 17₹10,205
31 Dec 18₹9,196
31 Dec 19₹9,151
31 Dec 20₹15,175
31 Dec 21₹18,232

SBI Healthcare Opportunities Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹395,578.
Net Profit of ₹95,578
Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 25 Jan 22

DurationReturns
1 Month -2%
3 Month -1.1%
6 Month -7%
1 Year 9.7%
3 Year 22.1%
5 Year 10.8%
10 Year
15 Year
Since launch 14.4%
Historical performance (Yearly) on absolute basis
YearReturns
2021 20.1%
2020 65.8%
2019 -0.5%
2018 -9.9%
2017 2.1%
2016 -14%
2015 27.1%
2014 56.8%
2013 26%
2012 37.1%
Fund Manager information for SBI Healthcare Opportunities Fund
NameSinceTenure
Tanmaya Desai1 Jun 1110.59 Yr.

Data below for SBI Healthcare Opportunities Fund as on 31 Dec 21

Equity Sector Allocation
SectorValue
Health Care94.68%
Basic Materials1.62%
Asset Allocation
Asset ClassValue
Cash3.34%
Equity96.31%
Debt0.35%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA
12%₹237 Cr2,800,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 20 | 500124
10%₹191 Cr390,000
Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 500087
9%₹170 Cr1,800,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
9%₹168 Cr360,000
Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | 543220
7%₹142 Cr3,200,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 20 | APOLLOHOSP
6%₹120 Cr240,000
↑ 40,000
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA
5%₹97 Cr1,320,000
↓ -280,000
Lupin Ltd (Healthcare)
Equity, Since 31 Jul 18 | 500257
5%₹95 Cr1,000,000
Medplus Health Services Ltd (Healthcare)
Equity, Since 31 Dec 21 | 543427
5%₹93 Cr911,178
↑ 911,178
Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Jul 20 | ALKEM
3%₹65 Cr180,000

Nifty Pharma Index

Generally Pharma Mutual funds follow similar composition of stocks tracking Nifty Pharma Index or CNX Pharma Index as this index is benchmark for Pharma Sector Mutual Funds.

Although Pharma Mutual Funds might not necessarily replicate same ratios and components.

Portfolio Characteristics

Portfolio Characteristics
Methodology Periodic Capped Free Float
Launch Date July 01, 2005
Base Date Jan 01, 2001
Base Value 1000
No. of Constituents 20
Calculation Frequency Real Time
Index Rebalancing Semi-Annually

Top Constituents by Weightage

Constituents companies of Nifty Pharma Index with weightage

As on November 30, 2021.

Stock Weightage
Sun Pharmaceutical Industries Ltd. 18.18
Divi's Laboratories Ltd. 13.89
Dr. Reddy's Laboratories Ltd. 12.69
Cipla Ltd. 11.03
Lupin Ltd. 4.75
Laurus Labs Ltd. 4.45
Aurobindo Pharma Ltd. 4.15
Gland Pharma Ltd. 3.95
Alkem Laboratories Ltd. 3.74
Biocon Ltd. 3.67

To more about index can be read on official website Nifty Pharma Index Document

Who Should Invest in Pharma Mutual Funds?

Being a sector-specific fund, pharma funds carry a huge risk of investment. Investors having an in-depth knowledge of the pharma and healthcare industry are only advised to invest. Also, the ability to bear a high-risk.

Investors who think the pharma sector will give good returns in the future or can perform stable in the long-run can invest.

Healthcare Sector in India

1. Public healthcare

Public healthcare is free for those who are below the poverty line. It encompasses 18% of total outpatient care and 44% of total inpatient care. Middle and upper class individuals tend to use public healthcare less than those with a lower standard of living. Additionally, females and elderly use public services more. The public health care system was originally developed in order to provide a means to healthcare access regardless of socioeconomic status. However, reliance on public and private healthcare sectors varies significantly between states. Several reasons are cited for relying on the private rather than public sector; the main reason at the national level is poor quality of care in the public sector, with more than 57% of households pointing to this as the reason for a preference for private health care.

Most of the public healthcare caters to the rural areas; and the poor quality arises from the reluctance of experienced healthcare providers to visit the rural areas. Consequently, the majority of the public healthcare system catering to the rural and remote areas relies on inexperienced and unmotivated interns who are mandated to spend time in public healthcare clinics as part of their curricular requirement. Other major reasons are distance of the public sector Facility, long wait times, and inconvenient hours of operation.

Different factors related to public healthcare are divided between the state and national government systems in terms of making decisions, as the national government addresses broadly applicable healthcare issues such as overall family welfare and prevention of major diseases, while the state governments Handle aspects such as local hospitals, public health, promotion and sanitation, which differ from state to state based on the particular communities involved. Interaction between the state and national governments does occur for healthcare issues that require larger scale resources or present a concern to the country as a whole.

Private healthcare

Since 2005, most of the healthcare capacity added has been in the private sector, or in partnership with the private sector. The private sector consists of 58% of the hospitals in the country, 29% of beds in hospitals, and 81% of doctors.

According to National Family Health Survey-3, the private medical sector remains the primary source of health care for 70% of households in urban areas and 63% of households in rural areas. The study conducted by IMS Institute for Healthcare Informatics in 2013, across 12 states in over 14,000 households indicated a steady increase in the usage of private healthcare facilities over the last 25 years for both Out Patient and In Patient services, across rural and urban areas. In terms of healthcare quality in the private sector, a 2012 study by Sanjay Basu et al., published in PLOS Medicine, indicated that health care providers in the private sector were more likely to spend a longer duration with their patients and conduct physical exams as a part of the visit compared to those working in public healthcare.

However, the high out of pocket cost from the private healthcare sector has led many households to incur Catastrophic Health Expenditure, which can be defined as health expenditure that threatens a household's capacity to maintain a basic standard of living. Costs of the private sector are only increasing. One study found that over 35% of poor Indian households incur such expenditure and this reflects the detrimental state in which Indian health care system is at the moment.

With government expenditure on health as a percentage of GDP falling over the years and the rise of private health care sector, the poor are left with fewer options than before to access health care services. Private insurance is available in India, as are various through government-sponsored health insurance schemes. According to the World Bank, about 25% of India's population had some form of health insurance in 2010. 2014 Indian government study found this to be an over-estimate, and claimed that only about 17% of India's population was insured.

How to Invest in Pharma Sector Funds Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.

  2. Complete your Registration and KYC Process

  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!

    Get Started

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
How helpful was this page ?
Rated 4.4, based on 35 reviews.
POST A COMMENT

Yogesh Kumar Juneja , posted on 5 Sep 21 12:30 PM

Please send list of funds which has the option of changing the sector of funds so that overall performance of mutual funds are always very good. Thanks and Regards

Shailendra, posted on 24 Jul 19 8:02 PM

Are largecap is best investment on longterm

1 - 2 of 2